33 unknown. 33 Phase 2, 10 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 33 | Unknown 33 |
| Phase 1 | 10 | Unknown 10 |
| Phase 3 | 3 | Unknown 3 |
Follow Motor Neuron Disease: new trials by email Literature Review of Motor Neuron Disease trials Research Report on Motor Neuron Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MRG-001 in Patients With Amyotrophic Lateral Sclerosis MRG-001 - Amyotrophic Lateral Sclerosis, Lou Gehrig Disease | Phase 2 | Unknown | MedRegen LLC | 10 | 2025-07-01 | 2024-08-23 |
| Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients Salbutamol, Placebo - Walking Capacity, Amyotrophic Lateral Sclerosis | Phase 2 | Unknown | Assistance Publique - Hôpitaux de Paris | 36 | 2024-09-01 | 2024-04-12 |
| Toxicity and Efficacy Evaluation of Topical Minoxidil in Acne Vulgaris topical minoxidil in Acne Vulgaris - Acne Vulgaris | Phase 1 / Phase 2 | Unknown | Chang Gung Memorial Hospital | 26 | 2023-07-11 | 2023-11-03 |
| A Double-blind Randomised, Placebo-controlled Clinical Trial to Test Ambroxol Treatment in ALS Ambroxol, Placebo - Amyotrophic Lateral Sclerosis | Phase 2 | Unknown | The Florey Institute of Neuroscience and Mental Health | 50 | 2023-06-13 | 2023-09-07 |
| Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients with Spinal Muscular Atrophy Type 1 EXG001-307 injection - Spinal Muscular Atrophy Type I | Phase 1 / Phase 2 | Unknown | Guangzhou Jiayin Biotech Ltd | 12 | 2023-02-16 | 2024-09-19 |
| NF-κB Inhibition in Amyotrophic Lateral Sclerosis Withania somnifera, Placebo - ALS | Phase 2 | Unknown | Sunnybrook Health Sciences Centre | 75 | 2021-10-19 | 2022-06-06 |
| Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS AMX0035 - ALS | Phase 1 / Phase 2 | Unknown | Amylyx Pharmaceuticals Inc. | 14 | 2021-08-05 | 2023-07-24 |
| Clinical Trial on the Use of Cell Therapy in the Treatment of Patients With Amyotrophic Lateral Sclerosis MNC (Mononuclear cells), Placebo / Saline - ALS (Amyotrophic Lateral Sclerosis) | Phase 2 | Unknown | Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia | 100 | 2021-05-01 | 2021-04-19 |
| The Evaluation of the Effect of Mesenchymal Stem Cells on the Immune System of Patients With ALS Mesenchymal stem cells isolated from Wharton's jelly - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Unknown | Polski Bank Komorek Macierzystych JSC (PBKM) | 20 | 2020-12-02 | 2022-05-03 |
| The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of ALS Scopolamine, atropine, edaravone and dexmedetomidine, Edaravone - Amyotrophic Lateral Sclerosis, Respiratory Function | Phase 2 | Unknown | Ruijin Hospital | 30 | 2020-11-01 | 2020-10-14 |
| Efficacy and Safety of Nitrazine in the Treatment of ALS Nitrofurazone Group 1, Nitroketazine Group 2, placebo group - Amyotrophic Lateral Sclerosis | Phase 2 | Unknown | Peking University Third Hospital | 150 | 2020-07-01 | 2021-07-06 |
| The Treatment of Amyotrophic Lateral Sclerosis With Huollingshengji Granules Huolingshengji Granules, Riluzole tablet - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Unknown | Peking University Third Hospital | 144 | 2020-06-01 | 2021-07-08 |
| Low Dose IL-2 in the Treatment of Immune-associated ALS Syndrome IL-2 - Amyotrophic Lateral Sclerosis | Phase 2 | Unknown | Peking University Third Hospital | 13 | 2020-01-01 | 2021-08-18 |
| CuATSM Compared With Placebo for Treatment of ALS/MND Cu(II)ATSM, Placebos - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Unknown | Collaborative Medicinal Development Pty Limited | 80 | 2019-09-30 | 2019-11-06 |
| The Efficacy and Safety of Vitamin E Mixed Tocotrienols In Patients With Amyotrophic Lateral Sclerosis (ALS) Tocotrienols, Placebo - Amyotrophic Lateral Sclerosis | Phase 2 | Unknown | University of Malaya | 20 | 2019-06-17 | 2019-10-25 |
| Outcomes Mandate National Integration With Cannabis as Medicine Cannabis, Medical, RYAH-Medtech Inhaler - Chronic Pain, Chronic Pain Syndrome | Phase 2 | Unknown | OMNI Medical Services, LLC | 200000 | 2018-12-01 | 2022-06-02 |
| ALS Treatment Extension Study Cu(II)ATSM - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Unknown | Collaborative Medicinal Development Pty Limited | 28 | 2018-01-18 | 2022-02-17 |
| A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS) Pimozide 2mg/day (current) or 4 mg/day (study initiation), Placebo Oral Tablet - ALS, Amyotrophic Lateral Sclerosis | Phase 2 | Unknown | University of Calgary | 100 | 2017-10-27 | 2020-05-28 |
| Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS) Edaravone, Riluzole - Neuromuscular Diseases | Phase 2 / Phase 3 | Unknown | Isfahan University of Medical Sciences | 20 | 2017-03-16 | 2019-03-27 |
| Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs) Cabazitaxel, Antihistamine, Corticosteroid - Circulating Tumor Cell, Metastatic Prostate Cancer | Phase 2 | Unknown | Erasmus Medical Center | 140 | 2017-02-21 | 2021-08-20 |
Showing 20 of 33. Sign in to see all of them.
Amyotrophic Lateral Sclerosis (28) · Bulbo-Spinal Atrophy, X-Linked (3) · Neuromuscular Diseases (2) · Spinal Muscular Atrophies of Childhood (2) · Acne Vulgaris (1) · Acquired Immunodeficiency Syndrome (1) · Anemia, Sickle Cell (1) · Anxiety Disorders (1) · Autistic Disorder (1) · Bipolar Disorder (1) · Brain Injuries, Traumatic (1) · Breast Neoplasms (1) · Bulbar Palsy, Progressive (1) · COVID-19 (1)
Central Nervous System Diseases (33) · Spinal Cord Diseases (33) · Nervous System Diseases (32) · Neurodegenerative Diseases (32) · Neuromuscular Diseases (31) · Metabolic Diseases (28) · Nutritional and Metabolic Diseases (28) · Proteostasis Deficiencies (28) · TDP-43 Proteinopathies (28) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Genetic Diseases, Inborn (6) · Heredodegenerative Disorders, Nervous System (6) · Muscular Atrophy, Spinal (5) · Genetic Diseases, X-Linked (3)
Edaravone (2) · Pimozide (2) · Riluzole (2) · copper (II) diacetyl-di(N(4)-methylthiosemicarbazone) (2) · Adrenal Cortex Hormones (1) · Albuterol (1) · Ambroxol (1) · Anastrozole (1) · Antiemetics (1) · Aromatase Inhibitors (1) · Ashwagandha (1) · Atropine (1) · Cell- and Tissue-Based Therapy (1) · Copper (1) · Dexmedetomidine (1)
Peking University Third Hospital (4) · Collaborative Medicinal Development Pty Limited (2) · University of Calgary (2) · Amylyx Pharmaceuticals Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · Chang Gung Memorial Hospital (1) · Erasmus Medical Center (1) · Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia (1) · General Hospital of Chinese Armed Police Forces (1) · Guangzhou Jiayin Biotech Ltd (1) · Hanyang University Seoul Hospital (1) · Isfahan University of Medical Sciences (1) · MedRegen LLC (1) · Neuralstem Inc. (1) · OMNI Medical Services, LLC (1)
China (9) · United States (4) · Australia (3) · Canada (3) · Iran (2) · Brazil (1) · France (1) · Italy (1) · Japan (1) · Malaysia (1) · Netherlands (1) · Poland (1) · South Korea (1) · Spain (1) · Taiwan (1)
Dongsheng Fan (3) · Dominic Rowe, MD (2) · Agessandro Abrahao, MD, MSc (1) · Alessandra Lugaresi, MD, PhD (1) · Ali R Ahmadi, MD PhD (1) · Amir Ali Hamidieh, MD (1) · Bradley Turner (1) · Cheng-Lung Hsu, Profesor (1) · David Schultz (1) · Dongsheng Fan, MD, PhD (1) · Dr. Ryan O Lakin, MD JD (1) · Fei Xu, MD (1) · Gerson Chadi, MD, PhD (1) · Hiide Yoshino, M.D. (1) · Jun Liu, Professor (1)
PMID 24820540, PMID 25324884, PMID 31434793, PMID 37633275, PMID 38011420, PMID 40458203